Cassava Sciences warned that the U.S. Food and Drug Administration might order a clinical hold on the company’s studies for the Alzheimer’s drug simufilam in 2022 after learning that two of its competitors received hold orders for similar research efforts.
More than half of the first 21 brains donated to the Australian Sports Brain Bank by former athletes showed signs of chronic traumatic encephalopathy (CTE), a degenerative disease caused by repeated concussions, a study showed.
Shares of Cassava Sciences were up more than 5% in premarket trading on February 11 after the U.S. Food and Drug Administration denied a Citizen Petition filed during 2021 on behalf of short-selling clients who sought to suspend the company’s Alzheimer’s clinical trials.
An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.
With $30 million in Series A funding, Tranquis Therapeutics launches with a mission of revolutionizing the management of neurodegenerative and aging-related diseases through the advancement of a novel immuno-neurology treatment approach.
A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.
Researchers at Washington University School of Medicine in St. Louis found further evidence that microglia are the key link between the accumulation of abnormal proteins, including beta-amyloid and tau, in the brain and the actual brain damage observed in Alzheimer’s patients.
